Deal details

The agreement centers on the discovery of mini-proteins — small protein molecules that Astellas intends to develop as part of its drug discovery pipeline. The total deal value is $400 million, encompassing upfront payments and potential milestones as outlined in the partnership between the two companies.

AI Proteomics applies artificial intelligence to protein design and discovery, and the collaboration will leverage that technology to identify mini-protein candidates for Astellas.

What remains unclear

The precise breakdown between upfront payments and milestone-based compensation was not specified in the available information, nor were details on which therapeutic areas the mini-protein programs will target.

The partnership reflects the growing use of AI-driven protein design in pharmaceutical discovery, with established drugmakers partnering with AI specialists to expand their pipelines.

Astellas' $400 million agreement with AI Proteomics for mini-protein discovery is True.